Does the media favor AXSM or JAZZ?

In the previous week, Jazz Pharmaceuticals had 2 more articles in the media than Axsome Therapeutics. MarketBeat recorded 7 mentions for Jazz Pharmaceuticals and 5 mentions for Axsome Therapeutics. Jazz Pharmaceuticals' average media sentiment score of 1.47 beat Axsome Therapeutics' score of 0.50 indicating that Jazz Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Axsome Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Jazz Pharmaceuticals 5 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer AXSM or RVMD?

In the previous week, Revolution Medicines had 6 more articles in the media than Axsome Therapeutics. MarketBeat recorded 11 mentions for Revolution Medicines and 5 mentions for Axsome Therapeutics. Revolution Medicines' average media sentiment score of 0.58 beat Axsome Therapeutics' score of 0.50 indicating that Revolution Medicines is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Axsome Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Revolution Medicines 4 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to AXSM or ONC?

In the previous week, BeOne Medicines had 8 more articles in the media than Axsome Therapeutics. MarketBeat recorded 13 mentions for BeOne Medicines and 5 mentions for Axsome Therapeutics. Axsome Therapeutics' average media sentiment score of 0.50 beat BeOne Medicines' score of 0.22 indicating that Axsome Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Axsome Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive BeOne Medicines 3 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor AXSM or MRNA?

In the previous week, Moderna had 19 more articles in the media than Axsome Therapeutics. MarketBeat recorded 24 mentions for Moderna and 5 mentions for Axsome Therapeutics. Moderna's average media sentiment score of 0.55 beat Axsome Therapeutics' score of 0.50 indicating that Moderna is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Axsome Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Moderna 8 Very Positive mention(s) 4 Positive mention(s) 11 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Axsome Therapeutics (AXSM) Competitors

$244.77 +3.65 (+1.51%)

Closing price 04:00 PM Eastern

Extended Trading

$242.69 -2.08 (-0.85%)

As of 07:02 PM Eastern

Compare

AXSM vs. JAZZ, RVMD, TEVA, ONC, and MRNA

Should you buy Axsome Therapeutics stock or one of its competitors? MarketBeat compares Axsome Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Axsome Therapeutics include Jazz Pharmaceuticals (JAZZ), Revolution Medicines (RVMD), Teva Pharmaceutical Industries (TEVA), BeOne Medicines (ONC), and Moderna (MRNA). These companies are all part of the "medical" sector.

How does Axsome Therapeutics compare to Jazz Pharmaceuticals?

Axsome Therapeutics (NASDAQ:AXSM) and Jazz Pharmaceuticals (NASDAQ:JAZZ) are both large-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, dividends, earnings, media sentiment, risk and profitability.

In the previous week, Jazz Pharmaceuticals had 2 more articles in the media than Axsome Therapeutics. MarketBeat recorded 7 mentions for Jazz Pharmaceuticals and 5 mentions for Axsome Therapeutics. Jazz Pharmaceuticals' average media sentiment score of 1.47 beat Axsome Therapeutics' score of 0.50 indicating that Jazz Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Axsome Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
Jazz Pharmaceuticals	5 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Axsome Therapeutics presently has a consensus target price of $258.95, suggesting a potential upside of 5.79%. Jazz Pharmaceuticals has a consensus target price of $246.06, suggesting a potential upside of 2.11%. Given Axsome Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Axsome Therapeutics is more favorable than Jazz Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Axsome Therapeutics	1 Sell rating(s)	0 Hold rating(s)	19 Buy rating(s)	1 Strong Buy rating(s)	2.95
Jazz Pharmaceuticals	0 Sell rating(s)	3 Hold rating(s)	16 Buy rating(s)	0 Strong Buy rating(s)	2.84

Jazz Pharmaceuticals has a net margin of 0.66% compared to Axsome Therapeutics' net margin of -26.59%. Jazz Pharmaceuticals' return on equity of 14.56% beat Axsome Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Axsome Therapeutics	-26.59%	-267.16%	-28.53%
Jazz Pharmaceuticals	0.66%	14.56%	5.25%

Axsome Therapeutics has a beta of 0.61, indicating that its share price is 39% less volatile than the broader market. Comparatively, Jazz Pharmaceuticals has a beta of 0.32, indicating that its share price is 68% less volatile than the broader market.

Axsome Therapeutics has higher earnings, but lower revenue than Jazz Pharmaceuticals. Jazz Pharmaceuticals is trading at a lower price-to-earnings ratio than Axsome Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Axsome Therapeutics	$638.50M	19.73	-$183.17M	-$3.73	N/A
Jazz Pharmaceuticals	$4.44B	3.41	-$356.15M	-$0.02	N/A

81.5% of Axsome Therapeutics shares are held by institutional investors. Comparatively, 89.1% of Jazz Pharmaceuticals shares are held by institutional investors. 20.6% of Axsome Therapeutics shares are held by company insiders. Comparatively, 4.1% of Jazz Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

Axsome Therapeutics beats Jazz Pharmaceuticals on 9 of the 17 factors compared between the two stocks.

How does Axsome Therapeutics compare to Revolution Medicines?

Axsome Therapeutics (NASDAQ:AXSM) and Revolution Medicines (NASDAQ:RVMD) are both large-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, profitability, risk, valuation, institutional ownership, dividends, media sentiment and earnings.

In the previous week, Revolution Medicines had 6 more articles in the media than Axsome Therapeutics. MarketBeat recorded 11 mentions for Revolution Medicines and 5 mentions for Axsome Therapeutics. Revolution Medicines' average media sentiment score of 0.58 beat Axsome Therapeutics' score of 0.50 indicating that Revolution Medicines is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Axsome Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
Revolution Medicines	4 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

81.5% of Axsome Therapeutics shares are owned by institutional investors. Comparatively, 94.3% of Revolution Medicines shares are owned by institutional investors. 20.6% of Axsome Therapeutics shares are owned by insiders. Comparatively, 7.6% of Revolution Medicines shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Revolution Medicines has a net margin of 0.00% compared to Axsome Therapeutics' net margin of -26.59%. Revolution Medicines' return on equity of -83.22% beat Axsome Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Axsome Therapeutics	-26.59%	-267.16%	-28.53%
Revolution Medicines	N/A	-83.22%	-59.06%

Axsome Therapeutics has a beta of 0.61, suggesting that its stock price is 39% less volatile than the broader market. Comparatively, Revolution Medicines has a beta of 1.4, suggesting that its stock price is 40% more volatile than the broader market.

Axsome Therapeutics presently has a consensus price target of $258.95, suggesting a potential upside of 5.79%. Revolution Medicines has a consensus price target of $134.50, suggesting a potential downside of 28.18%. Given Axsome Therapeutics' higher probable upside, analysts plainly believe Axsome Therapeutics is more favorable than Revolution Medicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Axsome Therapeutics	1 Sell rating(s)	0 Hold rating(s)	19 Buy rating(s)	1 Strong Buy rating(s)	2.95
Revolution Medicines	1 Sell rating(s)	1 Hold rating(s)	17 Buy rating(s)	3 Strong Buy rating(s)	3.00

Axsome Therapeutics has higher revenue and earnings than Revolution Medicines. Axsome Therapeutics is trading at a lower price-to-earnings ratio than Revolution Medicines, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Axsome Therapeutics	$638.50M	19.73	-$183.17M	-$3.73	N/A
Revolution Medicines	$11.58M	3,438.32	-$1.13B	-$7.07	N/A

Summary

Revolution Medicines beats Axsome Therapeutics on 10 of the 17 factors compared between the two stocks.

How does Axsome Therapeutics compare to Teva Pharmaceutical Industries?

Axsome Therapeutics (NASDAQ:AXSM) and Teva Pharmaceutical Industries (NYSE:TEVA) are both large-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, analyst recommendations, risk, media sentiment, profitability, institutional ownership, valuation and earnings.

Teva Pharmaceutical Industries has higher revenue and earnings than Axsome Therapeutics. Axsome Therapeutics is trading at a lower price-to-earnings ratio than Teva Pharmaceutical Industries, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Axsome Therapeutics	$638.50M	19.73	-$183.17M	-$3.73	N/A
Teva Pharmaceutical Industries	$17.26B	2.26	$1.41B	$1.33	25.52

In the previous week, Teva Pharmaceutical Industries had 6 more articles in the media than Axsome Therapeutics. MarketBeat recorded 11 mentions for Teva Pharmaceutical Industries and 5 mentions for Axsome Therapeutics. Teva Pharmaceutical Industries' average media sentiment score of 1.32 beat Axsome Therapeutics' score of 0.50 indicating that Teva Pharmaceutical Industries is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Axsome Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
Teva Pharmaceutical Industries	9 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

81.5% of Axsome Therapeutics shares are owned by institutional investors. Comparatively, 54.1% of Teva Pharmaceutical Industries shares are owned by institutional investors. 20.6% of Axsome Therapeutics shares are owned by company insiders. Comparatively, 0.5% of Teva Pharmaceutical Industries shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Axsome Therapeutics currently has a consensus target price of $258.95, suggesting a potential upside of 5.79%. Teva Pharmaceutical Industries has a consensus target price of $41.78, suggesting a potential upside of 23.11%. Given Teva Pharmaceutical Industries' higher possible upside, analysts clearly believe Teva Pharmaceutical Industries is more favorable than Axsome Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Axsome Therapeutics	1 Sell rating(s)	0 Hold rating(s)	19 Buy rating(s)	1 Strong Buy rating(s)	2.95
Teva Pharmaceutical Industries	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.80

Axsome Therapeutics has a beta of 0.61, suggesting that its share price is 39% less volatile than the broader market. Comparatively, Teva Pharmaceutical Industries has a beta of 0.84, suggesting that its share price is 16% less volatile than the broader market.

Teva Pharmaceutical Industries has a net margin of 9.01% compared to Axsome Therapeutics' net margin of -26.59%. Teva Pharmaceutical Industries' return on equity of 43.53% beat Axsome Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Axsome Therapeutics	-26.59%	-267.16%	-28.53%
Teva Pharmaceutical Industries	9.01%	43.53%	8.19%

Summary

Teva Pharmaceutical Industries beats Axsome Therapeutics on 11 of the 17 factors compared between the two stocks.

How does Axsome Therapeutics compare to BeOne Medicines?

Axsome Therapeutics (NASDAQ:AXSM) and BeOne Medicines (NASDAQ:ONC) are both large-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, media sentiment, valuation, dividends, risk, institutional ownership, analyst recommendations and profitability.

81.5% of Axsome Therapeutics shares are held by institutional investors. Comparatively, 48.5% of BeOne Medicines shares are held by institutional investors. 20.6% of Axsome Therapeutics shares are held by insiders. Comparatively, 6.2% of BeOne Medicines shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

BeOne Medicines has a net margin of 8.94% compared to Axsome Therapeutics' net margin of -26.59%. BeOne Medicines' return on equity of 12.06% beat Axsome Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Axsome Therapeutics	-26.59%	-267.16%	-28.53%
BeOne Medicines	8.94%	12.06%	6.69%

Axsome Therapeutics has a beta of 0.61, meaning that its stock price is 39% less volatile than the broader market. Comparatively, BeOne Medicines has a beta of 0.49, meaning that its stock price is 51% less volatile than the broader market.

Axsome Therapeutics currently has a consensus price target of $258.95, suggesting a potential upside of 5.79%. BeOne Medicines has a consensus price target of $390.00, suggesting a potential upside of 36.86%. Given BeOne Medicines' higher possible upside, analysts plainly believe BeOne Medicines is more favorable than Axsome Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Axsome Therapeutics	1 Sell rating(s)	0 Hold rating(s)	19 Buy rating(s)	1 Strong Buy rating(s)	2.95
BeOne Medicines	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	2 Strong Buy rating(s)	2.93

BeOne Medicines has higher revenue and earnings than Axsome Therapeutics. Axsome Therapeutics is trading at a lower price-to-earnings ratio than BeOne Medicines, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Axsome Therapeutics	$638.50M	19.73	-$183.17M	-$3.73	N/A
BeOne Medicines	$5.74B	5.45	$286.93M	$4.47	63.75

In the previous week, BeOne Medicines had 8 more articles in the media than Axsome Therapeutics. MarketBeat recorded 13 mentions for BeOne Medicines and 5 mentions for Axsome Therapeutics. Axsome Therapeutics' average media sentiment score of 0.50 beat BeOne Medicines' score of 0.22 indicating that Axsome Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Axsome Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
BeOne Medicines	3 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

BeOne Medicines beats Axsome Therapeutics on 10 of the 17 factors compared between the two stocks.

How does Axsome Therapeutics compare to Moderna?

Axsome Therapeutics (NASDAQ:AXSM) and Moderna (NASDAQ:MRNA) are both large-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, earnings, media sentiment, risk, institutional ownership, valuation and profitability.

81.5% of Axsome Therapeutics shares are held by institutional investors. Comparatively, 75.3% of Moderna shares are held by institutional investors. 20.6% of Axsome Therapeutics shares are held by insiders. Comparatively, 10.8% of Moderna shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Axsome Therapeutics has a beta of 0.61, meaning that its share price is 39% less volatile than the broader market. Comparatively, Moderna has a beta of 1.05, meaning that its share price is 5% more volatile than the broader market.

In the previous week, Moderna had 19 more articles in the media than Axsome Therapeutics. MarketBeat recorded 24 mentions for Moderna and 5 mentions for Axsome Therapeutics. Moderna's average media sentiment score of 0.55 beat Axsome Therapeutics' score of 0.50 indicating that Moderna is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Axsome Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
Moderna	8 Very Positive mention(s)	4 Positive mention(s)	11 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Axsome Therapeutics has higher earnings, but lower revenue than Moderna. Axsome Therapeutics is trading at a lower price-to-earnings ratio than Moderna, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Axsome Therapeutics	$638.50M	19.73	-$183.17M	-$3.73	N/A
Moderna	$1.94B	14.29	-$2.82B	-$8.15	N/A

Axsome Therapeutics has a net margin of -26.59% compared to Moderna's net margin of -143.55%. Moderna's return on equity of -26.64% beat Axsome Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Axsome Therapeutics	-26.59%	-267.16%	-28.53%
Moderna	-143.55%	-26.64%	-19.32%

Axsome Therapeutics presently has a consensus price target of $258.95, indicating a potential upside of 5.79%. Moderna has a consensus price target of $37.13, indicating a potential downside of 46.98%. Given Axsome Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Axsome Therapeutics is more favorable than Moderna.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Axsome Therapeutics	1 Sell rating(s)	0 Hold rating(s)	19 Buy rating(s)	1 Strong Buy rating(s)	2.95
Moderna	5 Sell rating(s)	11 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	1.83

Summary

Axsome Therapeutics beats Moderna on 10 of the 17 factors compared between the two stocks.

Get Axsome Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AXSM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AXSM vs. The Competition

Export

Metric	Axsome Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$12.60B	$3.63B	$6.76B	$12.60B
Dividend Yield	N/A	2.21%	2.66%	6.21%
P/E Ratio	-65.62	21.26	27.33	24.89
Price / Sales	19.73	347.28	564.71	115.42
Price / Cash	N/A	62.10	29.14	36.96
Price / Book	139.87	8.74	11.01	6.56
Net Income	-$183.17M	$23.81M	$3.57B	$336.70M
7 Day Performance	1.16%	3.64%	2.56%	3.31%
1 Month Performance	4.39%	1.64%	0.89%	1.68%
1 Year Performance	134.48%	69.47%	36.84%	31.96%

Axsome Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AXSM Axsome Therapeutics	1.9176 of 5 stars	$244.77 +1.5%	$258.95 +5.8%	+133.3%	$12.60B	$638.50M	N/A	380
JAZZ Jazz Pharmaceuticals	3.2024 of 5 stars	$237.72 +3.3%	$246.06 +3.5%	+122.4%	$14.45B	$4.27B	N/A	2,890	Positive News Analyst Upgrade
RVMD Revolution Medicines	1.6852 of 5 stars	$192.62 +5.8%	$132.78 -31.1%	+421.9%	$38.71B	$11.58M	N/A	250	Analyst Forecast
TEVA Teva Pharmaceutical Industries	4.8149 of 5 stars	$33.20 0.0%	$41.78 +25.8%	+98.2%	$38.19B	$17.26B	24.96	33,950	Positive News
ONC BeOne Medicines	4.7746 of 5 stars	$289.99 +3.6%	$390.00 +34.5%	+20.2%	$30.71B	$5.74B	64.87	12,000	Analyst Upgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:AXSM) was last updated on 6/30/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Axsome Therapeutics (AXSM) Competitors

AXSM vs. JAZZ, RVMD, TEVA, ONC, and MRNA

How does Axsome Therapeutics compare to Jazz Pharmaceuticals?

Summary

How does Axsome Therapeutics compare to Revolution Medicines?

Summary

How does Axsome Therapeutics compare to Teva Pharmaceutical Industries?

Summary

How does Axsome Therapeutics compare to BeOne Medicines?

Summary

How does Axsome Therapeutics compare to Moderna?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AXSM vs. The Competition

Axsome Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Axsome Therapeutics (AXSM) Competitors

AXSM vs. JAZZ, RVMD, TEVA, ONC, and MRNA

How does Axsome Therapeutics compare to Jazz Pharmaceuticals?

Does the media favor AXSM or JAZZ?

Do analysts rate AXSM or JAZZ?

Is AXSM or JAZZ more profitable?

Which has more risk & volatility, AXSM or JAZZ?

Which has better earnings & valuation, AXSM or JAZZ?

Do institutionals and insiders believe in AXSM or JAZZ?

Summary

How does Axsome Therapeutics compare to Revolution Medicines?

Does the media prefer AXSM or RVMD?

Do institutionals & insiders hold more shares of AXSM or RVMD?

Is AXSM or RVMD more profitable?

Which has more volatility and risk, AXSM or RVMD?

Do analysts prefer AXSM or RVMD?

Which has better valuation and earnings, AXSM or RVMD?

Summary

How does Axsome Therapeutics compare to Teva Pharmaceutical Industries?

Which has higher earnings & valuation, AXSM or TEVA?

Does the media favor AXSM or TEVA?

Do institutionals and insiders hold more shares of AXSM or TEVA?

Do analysts prefer AXSM or TEVA?

Which has more risk & volatility, AXSM or TEVA?

Is AXSM or TEVA more profitable?

Summary

How does Axsome Therapeutics compare to BeOne Medicines?

Do institutionals & insiders hold more shares of AXSM or ONC?

Is AXSM or ONC more profitable?

Which has more risk and volatility, AXSM or ONC?

Do analysts prefer AXSM or ONC?

Which has higher valuation & earnings, AXSM or ONC?

Does the media refer more to AXSM or ONC?

Summary

How does Axsome Therapeutics compare to Moderna?

Do institutionals and insiders have more ownership in AXSM or MRNA?

Which has more risk and volatility, AXSM or MRNA?

Does the media favor AXSM or MRNA?

Which has stronger valuation and earnings, AXSM or MRNA?

Is AXSM or MRNA more profitable?

Do analysts recommend AXSM or MRNA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AXSM vs. The Competition

Axsome Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools